HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection.

Abstract
A fixed-dose co-formulated antiretroviral drug containing elvitegravir, a new integrase strand transfer inhibitor, boosted by a novel pharmacokinetic enhancer cobicistat, and further containing the nucleoside pair of tenofovir and emtricitabine was recently approved by the U.S. Food and Drug Administration as a single-tablet, once-a-day treatment of HIV-1 infection in antiretroviral therapy-naive adults. This drug was found to be noninferior to two currently preferred antiretroviral regimens in clinical practice in two large, 48-week, phase III studies. Renal adverse effects limit its use to those with creatinine clearance > 70 mL/min; its considerable drug interaction potential requires care and attention when used. Nevertheless, the availability of this fixed-dose combination product is an important progress in the management of HIV infection for a number of reasons: It provides a third option for a one-pill, once-a-day antiretroviral regimen; it is the first such regimen that is not based on a non-nucleoside reverse transcriptase inhibitor; and it provides an alternative to ritonavir for the pharmaco-enhancement of other antiretroviral drugs.
AuthorsZ Temesgen
JournalDrugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 48 Issue 12 Pg. 765-71 (Dec 2012) ISSN: 1699-3993 [Print] Spain
PMID23243633 (Publication Type: Journal Article, Review)
CopyrightCopyright 2012 Prous Science, S.A.U. or its licensors. All rights reserved.
Chemical References
  • Anti-HIV Agents
  • Carbamates
  • Drug Combinations
  • HIV Integrase Inhibitors
  • Quinolones
  • Thiazoles
  • elvitegravir
  • Cobicistat
Topics
  • Anti-HIV Agents (administration & dosage, adverse effects, pharmacology, therapeutic use)
  • Antiretroviral Therapy, Highly Active (methods)
  • Carbamates (administration & dosage, adverse effects, pharmacology, therapeutic use)
  • Cobicistat
  • Drug Approval
  • Drug Combinations
  • Drug Interactions
  • Drug Resistance, Viral
  • HIV Infections (drug therapy, virology)
  • HIV Integrase Inhibitors (administration & dosage, adverse effects, pharmacology, therapeutic use)
  • Humans
  • Patient Safety
  • Quinolones (administration & dosage, adverse effects, pharmacology, therapeutic use)
  • Thiazoles (administration & dosage, adverse effects, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: